Evaluation in Mice of a Conjugate Vaccine for Cholera Made from Vibrio cholerae O1 (Ogawa) O-Specific Polysaccharide by Alam, Mohammad Murshid et al.
 
Evaluation in Mice of a Conjugate Vaccine for Cholera Made from
Vibrio cholerae O1 (Ogawa) O-Specific Polysaccharide
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Alam, M. M., M. K. Bufano, P. Xu, A. Kalsy, Y. Yu, Y. W.
Freeman, T. Sultana, et al. 2014. “Evaluation in Mice of a
Conjugate Vaccine for Cholera Made from Vibrio cholerae O1
(Ogawa) O-Specific Polysaccharide.” PLoS Neglected Tropical
Diseases 8 (2): e2683. doi:10.1371/journal.pntd.0002683.
http://dx.doi.org/10.1371/journal.pntd.0002683.
Published Version doi:10.1371/journal.pntd.0002683
Accessed February 19, 2015 3:20:55 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879750
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAEvaluation in Mice of a Conjugate Vaccine for Cholera
Made from Vibrio cholerae O1 (Ogawa) O-Specific
Polysaccharide
Mohammad Murshid Alam
1,2., Megan Kelly Bufano
1.,P e n gX u
3., Anuj Kalsy
1,Y .Y u
1, Y. Wu Freeman
1,
Tania Sultana
1,2, Md. Rasheduzzaman Rashu
1,2, Ishaan Desai
1, Grace Eckhoff
1, Daniel T. Leung
1,2,4,
Richelle C. Charles
1,4, Regina C. LaRocque
1,4, Jason B. Harris




2", W. F. Vann
8", Pavol Kova ´c ˇ
3", Edward T. Ryan
1,4,9"*
1Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2International Centre for Diarrheal Disease Research,
Bangladesh (ICDDR,B), Dhaka, Bangladesh, 3NIDDK, LBC, National Institutes of Health, Bethesda, Maryland, United States of America, 4Department of Medicine, Harvard
Medical School, Boston, Massachusetts, United States of America, 5Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America,
6Tulane University School of Medicine, New Orleans, Louisiana, United States of America, 7Department of Microbiology and Immunobiology, Harvard Medical School,
Boston, Massachusetts, United States of America, 8CBER, FDA, Laboratory of Bacterial Toxins, Bethesda, Maryland, United States of America, 9Department of Immunology
and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America
Abstract
Background: Protective immunity against cholera is serogroup specific. Serogroup specificity in Vibrio cholerae is
determined by the O-specific polysaccharide (OSP) of lipopolysaccharide (LPS). Generally, polysaccharides are poorly
immunogenic, especially in young children.
Methodology: Here we report the evaluation in mice of a conjugate vaccine for cholera (OSP:TThc) made from V. cholerae
O1 Ogawa O-Specific Polysaccharide–core (OSP) and recombinant tetanus toxoid heavy chain fragment (TThc). We
immunized mice intramuscularly on days 0, 21, and 42 with OSP:TThc or OSP only, with or without dmLT, a non-toxigenic
immunoadjuvant derived from heat labile toxin of Escherichia coli.
Principal Findings: We detected significant serum IgG antibody responses targeting OSP following a single immunization in
mice receiving OSP:TThc with or without adjuvant. Anti-LPS IgG responses were detected following a second immunization
in these cohorts. No anti-OSP or anti-LPS IgG responses were detected at any time in animals receiving un-conjugated OSP
with or without immunoadjuvant, and in animals receiving immunoadjuvant alone. Responses were highest following
immunization with adjuvant. Serum anti-OSP IgM responses were detected in mice receiving OSP:TThc with or without
immunoadjuvant, and in mice receiving unconjugated OSP. Serum anti-LPS IgM and vibriocidal responses were detected in
all vaccine cohorts except in mice receiving immunoadjuvant alone. No significant IgA anti-OSP or anti-LPS responses
developed in any group. Administration of OSP:TThc and adjuvant also induced memory B cell responses targeting OSP and
resulted in 95% protective efficacy in a mouse lethality cholera challenge model.
Conclusion: We describe a protectively immunogenic cholera conjugate in mice. Development of a cholera conjugate
vaccine could assist in inducing long-term protective immunity, especially in young children who respond poorly to
polysaccharide antigens.
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Cholera is a severe dehydrating diarrheal illness of humans
caused by organisms Vibrio cholerae O1 or O139 serogroup
organisms. V. cholerae O139 has largely disappeared and is
reported from just a few Asian countries [1]. Cholera affects 3–5
million people each year, killing ,100,000 annually, and cholera
is endemic in over 50 countries [2]. V. cholerae O1 can be
distinguished genotypically and phenotypically into classical and
El Tor biotypes [2] and Ogawa and Inaba serotypes. Ogawa
differs from Inaba only by the presence of a 2-O-methyl group in
the non-reducing terminal sugar of O-specific polysaccharide
(OSP) [3–5]. Currently, the global cholera pandemic is caused by
organisms V. cholerae O1, El Tor, organisms, with the prevalent
serotype fluctuating during cholera outbreaks, switching between
Ogawa and Inaba [1].
Protection against cholera is serogroup specific. Previous
infection with V. cholerae O139 provides no cross-protection from
cholera caused by V. cholerae O1, and vice versa [6–8]. Serogroup
specificity is largely determined by the O-specific polysaccharide
(OSP) of lipopolysacharide (LPS). OSP is attached to lipid A that
is part of the outer membrane of V. cholerae [9]. We have previously
shown that a synthetic neoglyconjugate cholera vaccine con-
taining a hexasaccharide of V. cholerae O1 Ogawa is protectively
immunogenic in mice [10–12]. We were therefore interested in
evaluating whether a cholera conjugate vaccine containing




The use of animals complied fully with relevant governmental
and institutional requirements, guidelines, and policies. This work
was approved by the Massachusetts General Hospital Subcom-
mittee on Research Animal Care (SRAC) – OLAW Assurance #
A3596-01; Protocol #2004N000192. The work adheres to the
USDA Animal Welfare Act, PHS Policy on Humane Care and
Use of Laboratory Animals, and the ‘‘ILAR Guide for the Care
and Use of Laboratory Animals’’.
Bacterial strains and media
V. cholerae O1 El Tor Ogawa strain X25049 [13] was used to
prepare LPS for use in vaccine preparation and immunological
assays, in addition to vibriocidal assays, and wild-type classical V.
cholerae O1 classical Ogawa strain O395 [10] was used in
vibriocidal assays and the neonatal challenge. Strains were grown
in Luria-Bertani broth.
Vaccine antigen
LPS was recovered from X25049, and OSP-core (OSPc) was
derived from LPS as previously described [9,14]. As a carrier
protein, recombinant tetanus toxoid heavy chain fragment (TThc)
was used [15,16]. TThc was prepared as a 52,108 Da recombi-
nant protein in E. coli BL21 (DE3) Star with a self-cleaving intein
tag using affinity and size exclusion chromatography, as previously
described [17].
Conjugation was carried out as previously described [14].
Briefly, 3,4-dimethoxy-3-cyclobutene-1, 2-dione (4.0 mg) was
added to a solution of Ogawa O-SP–core antigen (8.0 mg) in
pH 7 phosphate buffer (0.05 M, 400 mL) contained in a 2 mL V-
shaped reaction vessel, and the mixture was gently stirred at room
temperature for 48 h. The solution was transferred into an
Amicon Ultra (4 mL, 3K cutoff) centrifuge tube and dialyzed
against pure water (centrifugation at 4uC, 7,5006 g, 8 times,
35 min each time). The retentate was lyophilized to afford the O-
SP–core squarate monomethyl ester as white solid (7.4 mg, 91%).
TThc (3.2 mg) and the methyl squarate derivative of the Ogawa
O-SP–core antigen described above (7.4 mg) were weighed into a
1 mL V-shaped reaction vessel and 240 mL of 0.5 M pH 9 borate
buffer was added (to form ,5 mM solution with respect to the
antigen; antigen/carrier=20:1). A clear solution was formed. The
mixture was stirred at room temperature and the progress of the
reaction was monitored by SELDI-TOF MS at 24, 48, 72, 96, and
168 h, when no more increase of antigen/carrier ratio could be
observed. The mixture was transferred into an Amicon Ultra
(4 mL, 30 K cutoff) centrifuge tube and dialyzed (centrifugation at
4uC, 7,5006g, 8 times, 8 min each time) against 10 mM aqueous
ammonium carbonate. After lyophilization, 4.6 mg (83%, based
on TThc) of conjugate was obtained as a white solid. On the basis
of the molecular mass of the carrier (52,108 Da), conjugate
(90,000 Da, determined by SELDI TOF MS) and average MW of
the OSP antigen of 5,900 Da [14], the antigen/TThc ratio was
6.4:1 (conjugation efficiency, 32%) (figure 1). A corresponding
conjugate was made of OSP: bovine serum albumin (BSA; Sigma
#A-4503) using the same approach as described above for use in
immunologic assays. The OSP:BSA product contained 4.8 moles
OSP per BSA.
For these experiments, we used dmLT, a double mutant
derivative of Escherichia coli heat labile toxin (LT), as an
immunoadjuvant. dmLT (R192G/L211A) retains immunoadju-
vanticity with markedly reduced enterotoxicity [18]. dmLT was
prepared as previously described [18,19].
Immunization of mice and sampling
We immunized cohorts of 10–15, three to five week old Swiss
Webster female mice intramuscularly with OSP:TThc or OSP
(10 mg sugar per mouse; total 3 doses) with or without dmLT
(5 mg). Mice were immunized on days 0, 21, and 42. We collected
blood samples via tail bleeds on days 0, 21, 28, 42, 49 and 56.
Samples were collected, processed, aliquoted, and stored as
previously described [10,11]. For the memory B cell assay,
splenocytes were isolated after day 56 and processed for ELISPOT
as previously described [20].
Author Summary
Cholera is a severe dehydrating diarrheal illness of humans
caused by organisms Vibrio cholerae serogroups O1 or
O139 serogroup organisms. Protective immunity against
cholera is serogroup specific. Serogroup specificity in V.
cholerae is determined by the O-specific polysaccharide
(OSP) of lipopolysaccharide (LPS). Generally, polysaccha-
rides are poorly immunogenic, especially in young
children. Unfortunately, children bear a large burden of
cholera globally. Here we describe a novel cholera
conjugate vaccine and show that it induces immune
responses in mice, including memory responses, to OSP,
the T cell-independent antigen that probably is the target
of protective immunity to cholera. These responses were
highest following immunization of the vaccine with a
novel immunoadjuvant, dmLT. We also show that immu-
nization of mice with this conjugate vaccine protects
against challenge with wild-type V. cholerae. A protectively
immunogenic cholera conjugate vaccine that induces
long-term memory responses could have particular utility
in young children who are most at risk of cholera.
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We quantified anti-LPS and OSP IgG, IgM and IgA responses
in serum using standard enzyme-linked immunosorbent assay
(ELISA) protocols [10,11]. To assess anti-LPS antibody responses,
we coated ELISA plates with V. cholerae O1 Ogawa LPS (2.5 mg/
mL) in PBS [10,11]. To assess anti-OSP antibody responses, we
coated ELISA plates with OSP:BSA (1 mg/mL) in PBS. To each
well, we added 100 mL of serum (diluted 1:25 in 0.1% BSA in
phosphate buffered saline-Tween) and detected the presence of
antigen-specific antibodies using horseradish peroxidase-conjugat-
ed anti-mouse IgG, IgM or IgA antibody (diluted 1:1000 in 0.1%
BSA in phosphate buffered saline-Tween) (Southern Biotech,
Birmingham, AL). After 1.5 h incubation at 37uC, we developed
the plates with a 0.55 mg/mL solution of 2,29 0-azinobis (3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS; Sigma) with 0.03%
H2O2 (Sigma), and determined the optical density at 405 nm with
a Vmax microplate kinetic reader (Molecular Devices Corp.
Sunnyvale, CA). Plates were read for 5 min at 30 s intervals, and
the maximum slope for an optical density change of 0.2 U was
reported as millioptical density units per minute (mOD/min). We
normalized ELISA units (EU) by calculating the ratio of the optical
density of the test sample to that of a standard of pooled sera from
mice vaccinated with cholera vaccine from a previous study run on
the same plate. We characterized a responder as a $2-fold
increase in anti-LPS and OSP EU kinetic responses.
Measurement of serum vibriocidal responses
We assessed serum vibriocidal antibody titers against V. cholerae
X25049 in a micro-assay as previously described [21,22]. We
inactivated endogenous complement activity of mouse serum by
heating it for 1 hr at 56uC. We then added 50 ml aliquots of two-
fold serial dilutions of heat-inactivated sera in 0.15M saline (1:25
to 1:25,600) to wells of sterile 96-well tissue culture plates
containing 50 ml/well of V. cholerae X25049 (OD 0.1) in 0.15M
saline and 22% guinea pig complement (EMD Biosciences, San
Diego, CA). The plates were then incubated for 1 hr at 37uC.
150 ml of brain heart infusion broth (Becton Dickinson, Sparks,
MD) was added to each well, and plates were incubated for an
additional 1.5 h at 37uC, when optical density at 600 nm was
assessed. We calculated the vibriocidal titer as the dilution of
serum causing 50% reduction in optical density compared with
that of wells containing no serum [23,24]. We characterized a
responder as a $4-fold increase in vibriocidal titer.
Memory B cell responses
We assessed memory B-cell assays after the third round of
immunization based on previously described methods [20].
Briefly, we treated splenocytes from mice with 1 ml erythrocyte
lysis buffer (Sigma) and resuspended them in RPMI supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT), beta-
mercaptoethanol (Sigma, St. Louis, MO), R595 LPS (Alexis),
ConA stimulated supernatant and antibiotics (penicillin, strepto-
mycin). The ConA stimulated supernatant was made from naı ¨ve
mice splenocytes cultured with 2.5 ug/ml ConA and 20 ng/ml
PMA for 48 hours at 37uC in a humid atmosphere with 5% CO2.
We then cultured spleen cells in 96 well round-bottom plates
containing 1610
7 cells/mL irradiated syngeneic spleen cell feeders
(1200 rad) from naı ¨ve mice, and 1610
5 cells/well from immunized
mice in a total volume of 200 ml. Plates were then incubated at
37uC in a humid atmosphere with 5% CO2. After 6 days in
culture, cells were harvested and antigen-specific memory B cell
responses were measured by conventional ELISPOT method. We
assessed antigen-specific OSP and total IgG ELISPOT assays on
these cultured cells. Specifically, nitrocellulose bottom plates
(MAHAS4510, Millipore, Bedford, MA) were coated with
OSP:BSA (100 ng/well) or with goat anti-mouse IgG (Southern
Biotech, Birmingham, AL) or with keyhole limpet hemocyanin
(KLH; Pierce Biotechnology, Rockford, IL) (2.5 mg/mL, negative
control). After we blocked the plates with RPMI supplemented
with 10% FBS, we added the cultured cells to the wells and
incubated the plates for 5 h at 37uC in a humid atmosphere with
5% CO2. We then added biotinylated anti mouse IgGc (Southern
Biotech, Birmingham, AL) antibody at 1:1000, detected IgG
antibody expressing cells using horseradish peroxidase-conjugated
avidin-D (5 mg/ml, Vector Labs), and developed plates with
AEC (3 amino-9-ethyl-carbozole; Sigma). We used unstimulated
Figure 1. Structure of Ogawa OSP:TThc conjugate. 6.4 moles OSP per mole conjugate. TThc=recombinant tetanus toxoid heavy chain
fragment.
doi:10.1371/journal.pntd.0002683.g001
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characterized a responder as having .2 times total IgG cells with
stimulation versus no stimulation and .3 anti-OSP spots.
Neonatal challenge experiments
To assess protection afforded by immunization, we used a
cholera neonatal mouse challenge assay, as previously described
[10,11], using wild-type O1 Ogawa V. cholerae O395. In brief, we
removed three to five days old un-immunized CD-1 suckling mice
(n=20 mice/cohort) from dams two hours prior to inoculation.
We then administered to pups a 50 ml inoculum comprised of
2.3610
9 CFU of V. cholerae O395 mixed with a 1:250 dilution of
pooled day 56 serum from mice intramuscularly immunized with
the conjugate vaccine OSP:TThc with dmLT, or immunized with
dmLT alone. Following oral challenge, we kept neonates separate
from dams at 30uC and monitored animals every 3 hr for 36 hr,
after which surviving animals were euthanized.
Statistics and graphs
We compared data from different groups using Mann-Whitney
U tests. Within each group, comparisons of data from different
time points to baseline data (day 0) were carried out using
Wilcoxon Signed-Rank tests. Kaplan-Meier and log rank analysis
were carried out to compare survival curves in the neonatal
challenge study. All reported P values were two-tailed, with a
cutoff of P,0.05 considered a threshold for statistical significance.
We performed statistical analyses using GraphPad Prism 4
(GraphPad Software, Inc., La Jolla, CA).
Results
Analysis of OSP:TThc
We determined progress of conjugation and average carbohy-
drate content/carbohydrate–protein ratio of OSP:TThc by
Surface-Enhanced Laser Desorption–Ionization Mass Spectrom-
etry (SELDI) [25]. Similar to the matrix assisted variant (MALDI)
[26], this technique determines average degree of incorporation of
carbohydrate onto protein, as well as molecular weight distribution
in glycoconjugates. The SELDI analysis showed that the average
molecular mass of the conjugate was 90,150 Da. Subtracting from
that value the molecular mass of the recombinant protein TThc
carrier, 52,108 Da [17][27] the conjugate product molecular mass
increased by 38,042 Da. Based on the difference between m/z
values of subpeaks within the SELDI peak [14] ; also [28] the
molecular mass of the polymolecular OSP–core was determined to
average ,5,900 Da, representingattachment of various lengths of
OSP to core. The molecular mass of the conjugate determined by
SELDI, 91,150 Da, then indicated the molar ratio of OSP–
core:TThc to be ,6.4:1.
OSP-specific antibody responses
Following the first injection, we detected significant anti-OSP
serum IgG antibody responses in mice receiving OSP:TThc with
or without adjuvant (figure 2). Higher magnitude and response
rates (P,0.01) were observed in the cohort of animals receiving
conjugate vaccine with dmLT (response rate after two doses:
100%). No anti-OSP IgG responses were detected at any time in
animals receiving un-conjugated OSP only, with or without
immunoadjuvant, or in animals receiving immunoadjuvant alone.
Mice receiving OSP:TThc with or without immunoadjuvant and
mice receiving OSP alone developed anti-OSP IgM responses
(figure 3). IgM responses were only detected following a minimum
of two immunizations, and response frequency and magnitude
were highest in animals receiving OSP:TThc with adjuvant. No
significant IgA anti-OSP antibody was detected in any group (not
shown).
LPS-specific antibody responses
Significant serum anti-LPS IgG responses developed following a
second immunization in mice receiving conjugate with or without
adjuvant (figure 2). Anti-LPS IgM responses were detected in all
vaccine cohorts except in mice receiving immunoadjuvant alone
(figure 3). No significant anti-LPS IgA responses developed in any
group (not shown).
Vibriocidal responses
Low-level vibriocidal responses (magnitude and response
frequency) were detected in animals receiving unconjugated
OSP with or without adjuvant (figure 4). Administration of the
immunoadjuvant alone did not elicit any vibriocidal response in
animals.
Antigen-specific memory B cell responses
Antigen-specific IgG memory B-cell responses are shown in
table 1. OSP IgG specific memory B cell responses were detected
in 65% of mice immunized with conjugate vaccine and adjuvant.
18% and 22% of mice immunized with OSP in the presence of
Figure 2. Serum anti-OSP-BSA and anti-LPS IgG antibody
responses in mice intramuscularly immunized with OSP:TThc
(with dmLT), OSP (with dmLT), OSP:TThc (no dmLT), OSP (no
dmLT), or dmLT alone. Mean and standard error of the mean are
reported for each group. An asterisk denotes a statistically significant
difference (P,0.05) from baseline (day 0) titer. Responder frequencies
are also listed. #, statistically significant difference among the
compared cohorts (P,0.05).
doi:10.1371/journal.pntd.0002683.g002
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memory B cell responses, respectively. No OSP memory response
was detected in mice receiving dmLT alone.
Neonatal mouse challenge assay
We found a significant difference in survival between mice
challenged with wild-type V. cholerae O1 Ogawa O395 mixed with
sera collected from mice immunized with conjugate and adjuvant
(95% survival at 36 hours), compared to mice challenged using
sera from mice immunized with adjuvant alone (0% survival at
30 hours; 95% protection; P,0.0001) (figure 5).
Discussion
In this study, we demonstrate that a cholera conjugate vaccine
containing OSP recovered from V. cholerae is protectively
immunogenic and induces anti-OSP memory B cell responses in
mice. There is a growing body of evidence that anti-OSP
responses may be a prime mediator of protective immunity
against cholera. Protective immunity to cholera is serogroup
specific. Previous infection with V. cholerae O1 provides no
protection against O139 and vice versa. This is despite the fact
that O1 and O139 express essentially identical cholera toxins (CT)
and that O139 is thought to be a derivative of an O1 El Tor strain
with high-level homology of most genes in O1 El Tor and O139
[29,30]. O139 differs from O1 in its genes encoding OSP and in
the presence of capsule. The capsule of O139 is comprised of a
polysaccharide whose repeating unit is identical to the O139 OSP
[15]. The core moieties of O139 and O1 are identical [31]. These
data suggest that protection from cholera may be mediated by the
serogroup OSP of LPS.
Analysis of anti-OSP responses in cholera patients and their
potential role in protection has only recently been initiated [9,32].
There is however significant evidence that anti-LPS responses
correlate with protection from cholera [33,34]. The vibriocidal
response correlates with protection [35] and is largely comprised
of anti-LPS IgM responses [36]. We have recently shown that the
vibriocidal response can be largely adsorbed away by OSP [9].
Anti-LPS IgA responses in serum and stool have also been
associated with protection against cholera among household
contacts of cholera patients in Bangladesh [34]. Anti-LPS memory
B cell responses similarly correlate with protection against cholera
[33].
Currently, two oral killed cholera vaccines are WHO-
prequalified and commercially available [37]. One contains
approximately 10
11 killed V. cholerae O1 classical and El Tor
strain organisms (Ogawa and Inaba) and is supplemented with
Figure 3. Serum anti-OSP-BSA and anti-LPS IgM antibody
responses in mice intramuscularly immunized with OSP:TThc
(with dmLT), OSP (with dmLT), OSP:TThc (no dmLT), OSP (no
dmLT), or dmLT alone. Mean and standard error of the mean are
reported for each group. An asterisk denotes a statistically significant
difference (P,0.05) from baseline (day 0) titer. Responder frequencies
are also listed. #, statistically significant difference among the
compared cohorts (P,0.05).
doi:10.1371/journal.pntd.0002683.g003
Figure 4. Vibriocidal responses in mice intramuscularly immu-
nized with OSP:TThc (with dmLT), OSP (with dmLT), OSP:TThc
(no dmLT), OSP (no dmLT), or dmLT alone. The columns indicate
mean reciprocal end titers, and error bars represent the standard errors
of the mean. An asterisk denotes a statistically significant difference (P,
0.05) from baseline (day 0) titer. Responder frequencies are also listed.
#, statistically significant difference among the vaccine cohorts (P,
0.05).
doi:10.1371/journal.pntd.0002683.g004
Table 1. OSP-BSA specific IgG memory B cell responses in
mice immunized with different vaccine antigens.
Vaccine cohort Anti-OSP Anti-KLH
(%)* (%)*
OSP:TThc+dmLT 7/11 (65) 0/11 (0)
OSP+dmLT 2/11 (18) 0/11 (0)
OSP:TThc 2/9 (22) 0/9 (0)
OSP 1/9 (11) 0/9 (0)
dmLT 0/8 (0) 0/8 (0)
*Data are expressed as responder frequencies (see text).
doi:10.1371/journal.pntd.0002683.t001
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(WC:rBS; Dukoral, Crucell, Sweden). The other is bivalent,
containing killed classical and El Tor O1 organisms as well as an
O139 strain, and it does not contain supplemental cholera toxin
subunit (Shanchol, Shantabiotechnic-Sanofi, India). Following two
doses, these vaccines are 40–85% effective for 6–60 months
[13,37–39]. The level of response and duration of protection is
particularly decreased in children younger than 5 years of age,
compared to older children and adults [38,40,41], with booster
doses of Dukoral being recommended every 6 months for children
under 5 years of age [42]. In comparison, wild-type cholera is
associated with high level (90–100%) of protective immunity for at
least 3 years in volunteer challenge studies [43] and 3–10 year
protection in population-based studies [44]. The level and
duration of protection afforded by previous wild-type cholera
appears to be the same in young children and in older individuals
[45,46].
We have previously shown that wild-type cholera is associated
with a pro-inflammatory response even in young children in
Bangladesh, but that vaccination of Bangladeshi children with
WC-rBS induces a T-regulatory response [47]. We have also
shown that wild-type cholera induces anti-LPS memory B cell
responses, even in young children [45], but that children and adult
recipients of WC-rBS do not develop such responses [13,41]. In
addition, induction of memory B cell responses correlates with the
magnitude of early T cell responses in older recipients of WC-rBS
[47], but younger child recipients do not develop T cell responses
[47]. These observations may in part explain the lower level and
shorter duration of protection afforded by WC-rBS in young
children compared to that induced by wild-type disease. Unfor-
tunately, children bear a very large burden of cholera, especially in
endemic areas [48,49]. For instance, 40–80% of children in
Bangladesh develop serologic evidence of previous exposure to V.
cholerae by the age of 15 years [35,50], and in areas of India, there
is an estimated cholera incidence of 7 per 1000 for children less
than 5 years of age, compared to 2.19 in older children and 0.93 in
adults (.14 years age) [51]. There is thus a need for improved
cholera vaccines or immunization strategies capable of inducing
high-level and long-term immunity, especially in young children.
Immune responses targeting OSP may be critical in deter-
mining protective immunity from cholera. Since OSP is a T
cell-independent antigen, and because young children do not
develop prominent responses to polysaccharide antigens admin-
istered alone, we are particularly interested in developing a cholera
conjugate vaccine. Here we show that a cholera conjugate vaccine
is protectively immunogenic in mice and induces memory B cell
responses against OSP. Previous prototype cholera conjugates
have been developed [52][53][54] Our work contains a number of
innovative features. The conjugation process is carried out using
squaric acid chemistry, linking the glucosamine present in core
oligosaccharide to carrier protein via single point attachment [14].
This takes advantage of the core oligosaccharide, effectively using
it as a linker and resulting in a sun-burst display of OSP in a
manner that may mimic that present on the surface of V. cholerae.
Recent data suggest that the way LPS antigen is presented can
impact subsequent immune responses [55]. The fact that the
resulting conjugate in our analysis is not cross-linked and,
therefore, easier to characterize, together with conjugation
methodology that produces conjugates in a predictable manner
[56], maximizes the likelihood that vaccine generated in this way
and its immunological properties would be reproducible, which is
not the case with a number of conjugate vaccines for cholera
reported to date. Of note, we do not think that core oligosaccha-
ride contributes significantly to the protective immunity that we
observed since previous infection of humans with V. cholerae O1
does not provide protection from V. cholerae O139 and vice versa,
despite the presence of identical core oligosaccharides. We also
employed as carrier a recombinant immunogenic fragment of
tetanus toxoid that could be used as carrier in other vaccines as
well. Individuals at risk of cholera are often the most globally
disenfranchised and impoverished and may not have received all
recommended immunizations, including tetanus vaccine. In
addition, we used a novel immunoadjuvant, dmLT [18]. A
number of derivatives of the ADP-ribosylating LT molecule of E.
coli have been developed and evaluated in humans [18,57,58].
These molecules have in common their retained immunoadju-
vanticity but markedly diminished enterotoxicity [18]. We have
previously shown that transcutaneously applied CT or LT can act
as an immunoadjuvant [10,11]; here we show that low-dose dmLT
can also be safely administered parenterally in mice.
Our study is encouraging, but many questions remain. Would
an Inaba-based vaccine result in comparable results? Would a
response targeting Ogawa OSP cross protect against Inaba?
Previous human suggests it may not [59] Would an Inaba-based
vaccine protect against Ogawa-associated disease? Could a bi/
multi-valent conjugate vaccine be developed? Our vaccine
induced vibriocidal responses. Is this a reflection of the fact that
a significant component of the vibriocidal response can be
adsorbed with OSP [9] or are additional purification steps
required? How do conjugates using purified OSP compare to
glycoconjugate vaccines prepared from synthetic carbohydrates,
which are also under development [10,11,60,61]? Could other
immunoadjuvants be used? Is it possible to induce mucosal
responses, or would a parenteral cholera vaccine be sufficient
when most humans at risk of cholera are also at high risk of
tropical or environmental enteropathy with attendant leaking of
serum antibodies into the intestinal lumen?
Despite these questions, it is notable that previously produced
killed LPS-based whole cell parenteral cholera vaccines were
associated with up to 80% protection against disease in humans
[62]. Our data suggest that an improved parenteral cholera
conjugate vaccine can be developed, one that induces immune
responses, including memory B cell responses, to a normally T cell
independent antigen (OPS) that is the major target of protective
immunity to cholera. Furthermore, this conjugate vaccine can
Figure 5. Survival likelihood of neonatal CD-1 mice following
oral challenge with wild-type O1 Ogawa V. cholerae O395.
Three- to five-day-old pups (cohort size 20) were orally gavaged with
50 ml of a preparation containing 2.3610
9 CFU of wild type V. cholerae
O395 mixed with a 1:250 dilution of pooled day 56 serum from mice
intramuscularly immunized with conjugate vaccine (OSP:TThc) and
immunoadjuvantative dmLT, or dmLT alone. Survival curves were
compared by log rank testing.
doi:10.1371/journal.pntd.0002683.g005
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vaccine could have particular utility in young children who are
most at risk of cholera.
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